| Alector is a clinical stage biopharmaceutical company developing immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. Co.'s product candidate, AL001, modulates progranulin (PRGN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. AL101, Co.'s second product candidate in its PGRN portfolio, is designed to treat people suffering from more prevalent neurodegenerative diseases. AL003 is Co.'s second therapeutic candidate designed to treat patients with Alzheimer's disease. AL044 is Co.'s therapeutic candidate for neurodegeneration. We show 16 historical shares outstanding datapoints in our coverage of ALEC's shares outstanding history.|
Understanding the changing numbers of ALEC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ALEC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ALEC by allowing them to research ALEC shares outstanding history
as well as any other stock in our coverage universe.